Ascendis Pharma A/S Expected to Post Q3 2024 Earnings of ($1.96) Per Share (NASDAQ:ASND)

Ascendis Pharma A/S (NASDAQ:ASND - Free Report) - Investment analysts at Leerink Partnrs lowered their Q3 2024 earnings per share estimates for shares of Ascendis Pharma A/S in a research report issued to clients and investors on Monday, September 16th. Leerink Partnrs analyst J. Schwartz now expects that the biotechnology company will post earnings of ($1.96) per share for the quarter, down from their prior forecast of $0.85. The consensus estimate for Ascendis Pharma A/S's current full-year earnings is ($6.83) per share. Leerink Partnrs also issued estimates for Ascendis Pharma A/S's FY2024 earnings at ($8.38) EPS and FY2026 earnings at $1.48 EPS.

Several other research analysts have also recently commented on ASND. Bank of America raised their target price on shares of Ascendis Pharma A/S from $165.00 to $175.00 and gave the stock a "buy" rating in a report on Wednesday, September 4th. StockNews.com upgraded shares of Ascendis Pharma A/S from a "sell" rating to a "hold" rating in a research report on Thursday, September 5th. Oppenheimer reiterated an "outperform" rating and set a $190.00 price target (up previously from $180.00) on shares of Ascendis Pharma A/S in a report on Tuesday. Citigroup increased their price objective on Ascendis Pharma A/S from $178.00 to $207.00 and gave the stock a "buy" rating in a research note on Tuesday. Finally, The Goldman Sachs Group lifted their target price on Ascendis Pharma A/S from $180.00 to $200.00 and gave the company a "buy" rating in a research note on Tuesday. Two research analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company's stock. Based on data from MarketBeat, Ascendis Pharma A/S currently has a consensus rating of "Moderate Buy" and a consensus target price of $193.77.

Ascendis Pharma A/S Stock Performance

Shares of NASDAQ:ASND traded up $2.23 during midday trading on Thursday, reaching $151.11. The company had a trading volume of 121,040 shares, compared to its average volume of 436,443. The company has a fifty day simple moving average of $132.94 and a two-hundred day simple moving average of $136.52. The firm has a market cap of $8.80 billion, a price-to-earnings ratio of -15.49 and a beta of 0.63. Ascendis Pharma A/S has a 1-year low of $85.29 and a 1-year high of $161.00.

Institutional Trading of Ascendis Pharma A/S

Large investors have recently made changes to their positions in the stock. Private Ocean LLC bought a new stake in Ascendis Pharma A/S during the first quarter worth approximately $36,000. Quadrant Capital Group LLC grew its stake in Ascendis Pharma A/S by 90.4% in the 4th quarter. Quadrant Capital Group LLC now owns 318 shares of the biotechnology company's stock valued at $40,000 after buying an additional 151 shares during the last quarter. EverSource Wealth Advisors LLC raised its holdings in Ascendis Pharma A/S by 37.6% in the 4th quarter. EverSource Wealth Advisors LLC now owns 333 shares of the biotechnology company's stock worth $42,000 after acquiring an additional 91 shares during the period. GAMMA Investing LLC raised its holdings in Ascendis Pharma A/S by 52.0% in the 1st quarter. GAMMA Investing LLC now owns 298 shares of the biotechnology company's stock worth $45,000 after acquiring an additional 102 shares during the period. Finally, Barometer Capital Management Inc. acquired a new position in Ascendis Pharma A/S during the 4th quarter worth $126,000.

About Ascendis Pharma A/S

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates.